ArticleBMC cancer2025

Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study.

Lin Gui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.